MedPath

Comparison of two methods of administration of deferoxamine (intravenous and subcutaneous) in terms of impact on reducing iron overload in thalassemia patients who have suffered heart failure.

Phase 2
Conditions
Iron overload..
Abnormal level of blood mineral.
Registration Number
IRCT201206289827N2
Lead Sponsor
Kermanshah University of Medical Sciences and Health Services
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
42
Inclusion Criteria

suffering major Thalassemia and cardiac ejection fraction less than 50%.
Exclusion criteria: inflammatory disease; anemia and liver disorders.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum ferritin. Timepoint: 1 week after intervention (desferal administration). Method of measurement: Use of ELISA method, unit will be mg/L.
Secondary Outcome Measures
NameTimeMethod
Cardiac Ejection Fraction. Timepoint: 2 weeks after intervention. Method of measurement: Using Ecocardiography, the unit will be percent.
© Copyright 2025. All Rights Reserved by MedPath